9.00
price down icon2.07%   -0.19
after-market 시간 외 거래: 8.96 -0.04 -0.44%
loading

Viatris Inc 주식(VTRS)의 최신 뉴스

pulisher
11:26 AM

Xanax Maker Partially Blocks Hemp Co.'s 'Canvax' TM - Law360

11:26 AM
pulisher
Jul 29, 2025

What makes Viatris Inc. stock attractive to long term investorsSmart Safety Strategy With Real Data Analysis - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Anchoring Your Portfolio: Is VTRS Stock a Safe Harbor? - investchronicle.com

Jul 29, 2025
pulisher
Jul 29, 2025

What data driven models say about Viatris Inc.’s futureHigh Return Trade Roadmap with Setup Filters - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Influenza Vaccine Market is projected to grow to US$ 13.75 - openPR.com

Jul 29, 2025
pulisher
Jul 29, 2025

Lidocaine Vial Market Set to Witness Significant Growth by 2033 | - openPR.com

Jul 29, 2025
pulisher
Jul 29, 2025

Neurovascular Guidewires Market Outlook 2025 to 2035: Growth - openPR.com

Jul 29, 2025
pulisher
Jul 28, 2025

US Court Agrees To Throw Out Viatris Wegovy Infringement Case - insights.citeline.com

Jul 28, 2025
pulisher
Jul 28, 2025

How to interpret RSI for Viatris Inc. stockMomentum Stocks with Breakout Potential - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Why Viatris Inc. stock attracts strong analyst attention Daily Trade Monitor with Pattern Alerts - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Why is Viatris Inc. stock attracting strong analyst attentionInvest in high-yield stocks with confidence - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Viatris Inc. company’s balance sheetAchieve rapid financial growth with expert help - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Should I hold or sell Viatris Inc. stock in 2025Maximize portfolio value with expert tips - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How does Viatris Inc. compare to its industry peersFree Bull & Bear Market Updates - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How volatile is Viatris Inc. stock compared to the marketUnprecedented profit potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Competitive Positioning of Viatris Inc.: Is It Leading or LaggingFree Consultation - Newser

Jul 27, 2025
pulisher
Jul 26, 2025

Why Viatris Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What institutions are buying Viatris Inc. stock nowConsistent double returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Viatris Inc. stockTremendous wealth creation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria

Jul 24, 2025
pulisher
Jul 24, 2025

Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan

Jul 24, 2025
pulisher
Jul 24, 2025

Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Is Viatris Inc. a good long term investmentOutperformance with explosive growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Novo Nordisk loses Wegovy patent fight against generics maker Viatris - Endpoints News

Jul 23, 2025
pulisher
Jul 23, 2025

Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News

Jul 23, 2025
pulisher
Jul 23, 2025

Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

What to Expect From Viatris' Next Quarterly Earnings Report - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com

Jul 23, 2025
pulisher
Jul 22, 2025

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN

Jul 22, 2025
pulisher
Jul 21, 2025

Viatris down on late-stage trial setback for eye disorder therapy - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Inc. (VTRS) Stock Analysis: A Deep Dive Into Its 28% Potential Upside For Investors - DirectorsTalk Interviews

Jul 21, 2025
pulisher
Jul 20, 2025

Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Trend Tracker for (VTRS) - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest

Jul 19, 2025
drug_manufacturers_specialty_generic RDY
$14.10
price down icon 4.47%
$281.95
price down icon 5.25%
$136.76
price up icon 1.92%
$14.12
price down icon 1.88%
$71.84
price down icon 0.50%
자본화:     |  볼륨(24시간):